Ignite Creation Date:
2025-12-25 @ 1:39 AM
Ignite Modification Date:
2026-03-04 @ 3:00 PM
Study NCT ID:
NCT02632994
Status:
AVAILABLE
Last Update Posted:
2025-09-29
First Post:
2015-12-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000621566', 'term': 'LY3023414'}]}}, 'protocolSection': {'designModule': {'studyType': 'EXPANDED_ACCESS'}, 'statusModule': {'overallStatus': 'AVAILABLE', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'lastUpdateSubmitDate': '2025-09-26', 'studyFirstSubmitDate': '2015-12-15', 'studyFirstSubmitQcDate': '2015-12-15', 'lastUpdatePostDateStruct': {'date': '2025-09-29', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2015-12-17', 'type': 'ESTIMATED'}}, 'conditionsModule': {'conditions': ['Cancer']}, 'descriptionModule': {'briefSummary': 'This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'eligibilityCriteria': 'Inclusion Criteria:\n\n* To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.\n\nExclusion Criteria:\n\n* Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.'}, 'identificationModule': {'nctId': 'NCT02632994', 'briefTitle': 'Master Rollover Protocol for Continued Safety Assessment of Study Drug', 'organization': {'class': 'INDUSTRY', 'fullName': 'Eli Lilly and Company'}, 'officialTitle': 'Master Rollover Protocol for Continued Safety Assessment of Study Drug', 'orgStudyIdInfo': {'id': '16161'}, 'secondaryIdInfos': [{'id': 'I8I-MC-JYAA', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'LY2503029', 'type': 'DRUG', 'description': 'Administered orally.'}, {'name': 'LY3023414', 'type': 'DRUG', 'description': 'Administered orally.'}, {'name': 'LY3838915', 'type': 'DRUG', 'description': 'Administered orally.'}, {'name': 'LY3847429', 'type': 'DRUG', 'description': 'Administered orally.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '90505', 'city': 'Torrance', 'state': 'California', 'status': 'AVAILABLE', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '310-325-8252'}, {'name': 'Dr. Parvin Fatheddin Peddi', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'UCLA Medical Center', 'geoPoint': {'lat': 33.83585, 'lon': -118.34063}}, {'zip': '46804', 'city': 'Fort Wayne', 'state': 'Indiana', 'status': 'AVAILABLE', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '260-436-0800'}, {'name': 'Dr. Sunil Babu', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Fort Wayne Oncology & Hematology', 'geoPoint': {'lat': 41.1306, 'lon': -85.12886}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'status': 'AVAILABLE', 'country': 'United States', 'contacts': [{'role': 'CONTACT', 'phone': '615-329-7274'}, {'name': 'Dr. Howard A. Burris III', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Sarah Cannon Cancer Center', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}], 'centralContacts': [{'name': 'Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or', 'role': 'CONTACT', 'email': 'LillyTrials@Lilly.com', 'phone': '1-317-615-4559'}, {'name': 'Physicians interested in becoming principal investigators please contact', 'role': 'CONTACT', 'email': 'clinical_inquiry_hub@lilly.com'}], 'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Eli Lilly and Company'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}